Moderna, Inc. MRNA stock is trading lower on Monday. The COVID-19 vaccine maker and Merck & Co Inc. MRK reported five-year ...

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

Moderna (MRNA) closed at $41.95 in the latest trading session, marking a +2.29% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. Meanwhile, the Dow ...

NEW YORK - Debate over the need for COVID-19 booster shots is clouding the outlook for Moderna Inc's high-flying shares after ...

Moderna (MRNA) stock pushed meaningfully higher on Friday following reports that the biotech giant is leveraging its mRNA platform to develop a vaccine for hantavirus. The news, which arrived after a ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...